Rapport sur la santé dans le monde

Chapitre 2


Bibliographie

  • Access to antiretroviral treatment and care: the experience of the HIV Equity Initiative, Cange, Haiti. Genève, Organisation mondiale de la Santé, 2003 (http://www.who.int/hiv/pub/prev_care/en/Haiti_E_Final2004.pdf, consulté le 16 février 2004).
  • Antiretroviral therapy in primary health care: experience of the Khayelitsha programme in South Africa. Genève, Organisation mondiale de la Santé, 2003 (http://www.who.int/hiv/pub/prev_care/en/South_Africa_E.pdf, consulté le 16 février 2004).
  • Scaling up antiretroviral therapy: experience in Uganda. Genève, Organisation mondiale de la Santé, 2003 (Perspectives and Practice in Antiretroviral Treatment Series ; http://www.who.int/hiv/pub/prev_care/en/Uganda_E.pdf, consulté le 16 février 2004).
  • Farmer P, Léandre F, Mukherjee J, Gupta R, Tarter L et Kim JY. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy) [Traitement communautaire des stades avancés de l’infection à VIH : introduction du DOT-HAART (traitement antirétroviral hautement actif sous surveillance directe]. Bulletin of the World Health Organization 2001;79 (12): 1145–1151 (résumé en français).
  • Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic – United States. Morbidity and Mortality Weekly Report, 2003, 52:329–332.
  • The long-run economic costs of AIDS: theory and application to South Africa. Washington, D. C., Banque mondiale, 2003.
  • Rapport sur la santé dans le monde 2002 – Réduire les risques et promouvoir une vie saine. Genève : Organisation mondiale de la Santé, 2002.
  • Teixeira PR, Antônio Vitória M, Barcarolo J. The Brazilian experience in providing universal access to antiretroviral therapy (http://www.iaen.org/files.cgi/11066_part_1_n2_Teixeira.pdf, consulté le 16 février 2004).
  • Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA et al. Dramatic improvement in survival among Brazilian AIDS patients. AIDS, 2003, 17:1675–1682.
  • OMS/ONUSIDA. Treating 3 million by 2005: making it happen. The WHO strategy. Trois millions de personnes sous traitement d’ici 2005 : comment y parvenir. La stratégie de l’OMS. Genève, Organisation mondiale de la Santé, 2003.
  • Améliorer l’accès aux traitements antirétroviraux dans les pays à ressources limitées. Recommandations pour une approche de santé publique. Genève, Organisation mondiale de la Santé, avril 2002 (http://www.who.int/hiv/pub/prev_care/en/ScalingUP_FR.pdf, consulté le 16 février 2004).
  • Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS, 2003, 17:541–545.
  • Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. Journal of Acquired Immune Deficiency Syndromes, 2002, 31:378–383.
  • van der Ryst E, Kotze M, Joubert G, Steyn M, Pieters H, van der Westhuizen M et al. Correlation among total lymphocyte count, absolute CD4+ count, and CD4+ percentage in a group of HIV-1-infected South African patients. Journal of Acquired Immune Deficiency Syndromes, 1998, 19:238–244.
  • Stevens W, Kaye S, Corrah T. Antiretroviral therapy in Africa. BMJ, 2004, 328:280–282.
  • How will the 3 by 5 initiative deal with HIV drugs resistance? Genève, Organisation mondiale de la Santé, 2003 (WHO/HIV/2003.10; http://www.who.int/3by5/publications/briefs/en/drug_resistance.pdf, consulté le 17 février 2004).
  • Guidelines for surveillance of HIV drug resistance. Genève, Organisation mondiale de la Santé (projet de document en révision, http://www.who.int/3by5/publications/documents/hivdrugsurveillance/en/, consulté le 16 février 2004).
  • OMS/ONUSIDA. Estimated cost to reach the target of 3 million with access to antiretroviral therapy by 2005 («3 by 5»). Genève, Organisation mondiale de la Santé, (http://www.who.int/3by5/publications/documents/en/cost_of_3by5.pdf, consulté le 17 février 2004).
  • Chaudhury R, Bapna S. Effect of interventions on rational use of drugs. Document présenté à la Conference on the State of the Art and Future Directions, Chiang Mai (Thaïlande), 1–4 avril 1997 (http://www.who.int/dap-icium/posters/4D1_TEXT.html, consulté le 17 février 2004).
  • Zambia poverty reduction strategy paper 2002–2004. Lusaka, Ministry of Finance and National Planning, 2002.
  • Brindeiro RM, Diaz RS, Sabino EC, Morgado MG, Pires IL, Brigido L et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS, 2003, 17:1063–1069.
  • Szwarcwald CL, Bastos FI, Barcellos C, Esteves MAP, de Castilho EA. Dinâmica da epidemia de AIDS no Município do Rio de Janeiro, no período de 1988–1996: uma aplicação de análise estatística espaço-temporal. Cadernos de Saúde Pública, 2001, 17:1123–1140.
  • Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS, 2003, 17:1675–1682.

Documents connexes

Partager